A NEW METHOD TO REDUCE THE SIDE EFFECTS OF OCULAR BRACHYTHERAPY

Desarrollado por: Instituto de Investigación Biomédica de Bellvitge (IDIBELL)

Descripción

UNMET NEED:

Episcleral brachytherapy is the most widely used procedure for the treatment of Uveal melanoma. The problem of the treatment is the collateral damages to the healthy ocular tissue

PROPOSED SOLUTION:

Application of intravitreal nanoparticles in order to form an external shield covering the tumor surface

FEATURES:

  • This nanotechnology reduces the radiation dose for an effective treatment
  • Increasing the array of tumors capable to treat by standard Brachytherapy

Aplicaciones

The present technology may involve a radical change in the evolution patients suffering from uveal melanoma. It has been designed to protect the healthy eye structures from ionizing radiation, so that adequate treatment doses may be applied with less risk and severity of side effects. This technology will increase the array of tumors capable to treat by standard brachytherapy.

Estado de protección

The current project is in a pre-clinical stage and it is expected to be divided in two pre-clinical phases to develop a new device in ocular brachytherapy and perform the PoC in rabbits.

TRL: in vivo PoC

IP: Patent on Draft

Cooperación que se desea

Co-development

License agreement

Investment

Responsable: Área de Desarrollo de Negocio e Innovación // Oficina de Transferencia de Tecnología

Contacto (Tel./mail): 93 260 71 06 / Innovacio@idibell.cat

Estado:
En desarrollo, Transferible
Tecnología sanitaria:
Materiales y Dispositivos